1. Comparison of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in High Myopia
Jigna Joshi MD
Marian Macsai MD
Parag Majmudar MD
Vanee Virasch MD
A Collaboration between Northwestern and Rush University
Dr. Macsai is a member of the speakers bureau for Allergan and Alcon. Dr. Majmudar is a consultant for AMO.

2. Purpose
To compare outcomes of the Visian Implantable Collamer Lens with the Verisyse Phakic Intraocular Lens in patients with high myopia

3. Methods
A retrospective chart review of consecutive patients implanted with a phakic intraocular lens by one of two experienced surgeons.

4. Results Number of eyes Mean Age Sex Average follow up Verisyse 62 38
36 Female
26 Male
11 months
Visian 22 43
20 Female
2 Male

5. Results Pre-operative Spherical Equivalent Target Refraction
Post Operative Spherical Equivalent
Average post operative UCVA
Verisyse
-12.50
(-7.5 to )
-0.10
-0.41
20/37
Visian
-11.00
(-7 to )
-0.18
+0.25
20/33

6. Results Average Pre Operative Endothelial Cell Count
Average Post Operative Endothelial Cell Count
Verisyse
3412
2768
Visian
2482
2771

7. Results
Average loss of endothelial cells in the first 12 months was 4.4% in the Verisyse group and 2.5% in the Visian group.
Six (6) patients (8%) in the Verisyse group required enhancements with either PRK or LASIK
Four (4) patients (7.1%) in the Visian group required enhancement with LASIK.

8. Results
Three eyes required enlargement of Yag peripheral iridotomies within the first post operative month in the Visian group.
Four eyes developed mild peripheral anterior subcapsular opacities that were not visually significant in the Visian group.
No lenses required explantation

9. Limitations Small sample size
Endothelial cell counts in the Verisyse group were measured by two different techniques, one pre-op and one post-op, resulting in higher variability in that group
The inherent difference in lens position will result in different complications

10. Conclusion
Visual outcomes were similar in both intraocular lens groups.
Enhancement rates for residual refractive errors were similar in both intraocular lens groups.
Rate of endothelial cell loss was greater in the Verisyse, while the Visian group had more capsular opacities (visually insignificant).

11. Conclusion
The Visian ICL and the Verisyse Phakic IOL appear to be safe alternatives for the treatment of high myopia.
Post market approval outcomes are helpful for physicians considering including these techniques in their practice.